Koroma 1996

Methods	RCT Length of follow‐up: 6 months
Participants	All children living in endemic area Number analysed for primary outcome: 187 Age range: 6 to 10 years Inclusion criteria: selected (unclear how) urban and rural school primary children aged 6 to 10 years Exclusion criteria: not stated
Interventions	Single dose vs placebo Albendazole: 400 mg; Placebo.
Outcomes	Prevalence and intensity (arithmetic mean eggs/g); z‐scores (no reference category stated): weight‐for‐height, weight‐for‐age, and height‐for‐age.
Notes	Location: Sierra Leone Community category: 2 Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Randomized", no further details provided.
Allocation concealment (selection bias)	Unclear risk	No details reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No details reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	76% (187/247) of randomized participants were evaluated. Reasons for loss to follow‐up not reported. Inclusion of all randomized participants (number evaluable/number randomized): 76% (187/247).
Selective reporting (reporting bias)	Low risk	All stated outcomes reported.
Other bias	Low risk	No obvious other sources of bias.